PHS
AIMT

PFM Health Sciences’s Aimmune Therapeutics AIMT Stock Holding History

PFM Health Sciences’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-996,112
Closed -$25.2M – 89
2015
Q3 		$25.2M Buy
+996,112
New +$23.3M 0.71% 45

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PFM Health Sciences's AIMT Position: Q4 2015 in Review

PFM Health Sciences sold out of Aimmune Therapeutics (AIMT) in Q4 2015, closing a stake of 996,112 shares — an estimated $25.2M sold.

PFM Health Sciences first reported a position in AIMT in Q3 2015 and held it in 1 quarter. The position peaked at $25.2M in Q3 2015. 58 funds tracked by Wall St. Rank hold AIMT as of Q4 2015.

  • PFM Health Sciences reported no remaining Aimmune Therapeutics position as of Q4 2015 after selling out during the quarter.
  • PFM Health Sciences sold 996,112 Aimmune Therapeutics shares in Q4 2015, an estimated $25.2M.
  • PFM Health Sciences first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 1 quarter.
  • PFM Health Sciences's Aimmune Therapeutics position peaked at $25.2M in Q3 2015.
  • 58 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2015.

Based on PFM Health Sciences's 13F filing for Q4 2015, filed 16 Feb 2016.